SAN DIEGO, Calif., June 21, 2025 – Bloom Science, Inc., a clinical-stage biotech company focused on the development of novel therapies for metabolic and neurological disorders, today
today recognized Global ALS/MND Awareness Day and International Dravet Syndrome Awareness Day, honoring patients and families affected by neurodegenerative and rare neurological diseases.
Bloom’s research platform is focused on translating insights from microbiome biology into therapeutic approaches that address metabolic and neurological dysfunction.
“These awareness days remind us of the importance of continued innovation,” said Dr. Reyes. “We are committed to developing therapies that may improve quality of life for patients facing serious neurological conditions.”
About Bloom Science, Inc.
Bloom Science, Inc. is a clinical-stage biotech company focused on the development of novel first-in-class therapies for the treatment of metabolic and neurological disorders. Bloom’s research and development activities leverage its expertise in gut-brain axis biology, metabolism and the microbiome to develop innovative therapeutics designed to improve patients’ lives. Bloom’s clinical programs include BL-001, a first-in-class, orally delivered, Live Biotherapeutic Product (LBP) designed to replicate the therapeutic effects of the Ketogenic Diet. Bloom’s proprietary discovery platform, IrisRx™ enables a fundamentally different approach to developing medicines by harnessing our expanding insight into the Gut-Brain Axis to design and develop therapeutics that target novel biology with superior safety profiles. Bloom Science is advancing a deep pipeline of programs, focused in obesity, Dravet syndrome and DEEs, Amyotrophic Lateral Sclerosis (ALS), and other neurodegenerative and cognitive disorders.